Compare Inovio Pharmaceuticals Inc (INO) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while TotalEnergies SE trades at $87.6 (market cap $196.06B). The key difference: TotalEnergies SE is far larger — about 2496× Inovio Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TTE | |
|---|---|---|
Market Cap | $78.55M | $196.06B |
Sector | Health | Energy |
52-Week High | $2.87 | $93.60 |
52-Week Low | $0.66 | $57.39 |
Enterprise Value | $49.56M | $227.06B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
TotalEnergies SE (TTE) trades at $87.96, up 2.48% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while the company expands in renewables and gas projects. Valuation ratios like P/E of 11.01 and P/S of 0.98 appear attractive relative to sector peers.
The outlook is positive given strategic acquisitions and gas field developments, but risks include revenue declines and legal challenges. With a consensus price target of $94.00 and 57.58% buy ratings, the stock offers upside potential amid energy transition opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
